贝伐珠单抗治疗Heyde综合征难治性出血与输血依赖性贫血
本文报告一例Heyde综合征(主动脉瓣狭窄合并消化道血管发育不良出血)患者,因严重出血和贫血无法安全接受主动脉瓣置换所需的抗血小板或抗凝治疗。启用全身性贝伐珠单抗后,患者实现持久止血,血红蛋白恢复正常,摆脱红细胞输注和铁剂输注依赖,并成功启动阿司匹林治疗,随后顺利完成经导管主动脉瓣置换。
要点
- 贝伐珠单抗可用于Heyde综合征难治性消化道出血和输血依赖性贫血。
- 止血后患者成功启动既往失败的阿司匹林治疗并完成经导管主动脉瓣置换。
- 治疗期间血浆血管内皮生长因子水平升高,停药后恢复正常。
核心结论
- 全身性贝伐珠单抗可能为Heyde综合征难治性消化道出血的有效且安全的靶向治疗,有助于后续抗血小板治疗和主动脉瓣置换。
研究设计与样本
- 个案报告:一例Heyde综合征患者接受全身性贝伐珠单抗治疗,并监测血浆血管内皮生长因子水平。
主要发现
- 启用贝伐珠单抗后患者实现持久止血,血红蛋白恢复正常,摆脱红细胞输注和铁剂输注依赖。
- 阿司匹林治疗在既往失败的情况下成功启动。
- 持久止血使患者随后成功接受经导管主动脉瓣置换。
- 血浆血管内皮生长因子水平在启用贝伐珠单抗后反常升高,停药后恢复正常。
临床怎么用
- 对因严重出血和贫血无法安全接受抗血小板或抗凝治疗的Heyde综合征患者,可考虑全身性贝伐珠单抗作为止血手段。
- 贝伐珠单抗止血后可为启动抗血小板治疗及主动脉瓣置换创造条件。
局限性
- 为单个病例报告,疗效与安全性需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heyde syndrome, the co-occurrence of aortic stenosis and bleeding gastrointestinal (GI) angiodysplasia, is managed with aortic valve replacement. However, severe bleeding and anemia can preclude safe use of the antiplatelet or anticoagulant therapy required for this intervention. We present a case of the novel and successful treatment of severe, refractory bleeding and transfusion dependence with antiangiogenic therapy in a patient with Heyde syndrome. After systemic bevacizumab was initiated, the patient achieved durable hemostasis with normalization of hemoglobin and liberation from red cell transfusion and dependence on iron infusion; aspirin therapy was successfully initiated where it had previously failed. This durable hemostasis facilitated her subsequent successful transcatheter aortic valve replacement. Plasma vascular endothelial growth factor levels, which were monitored during therapy, paradoxically rose after bevacizumab was initiated but normalized after it was discontinued. Given the angiogenic dysregulation of Heyde syndrome, systemic bevacizumab may be an effective and safe targeted therapy for managing refractory GI bleeding, which thereby facilitates antiplatelet therapy and aortic valve replacement in these challenging cases. Additional investigation into the therapeutic role of inhibiting angiogenesis as a hemostatic modality in Heyde syndrome is warranted.
引用
- Song AB, Sakhuja R, Gracin NM, et al. Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome. Blood Adv. 2021. PMID: 34500461. doi:10.1182/bloodadvances.2021004810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。